NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Cadence Neuroscience

Cadence Neuroscience

Private
Redmond, WashingtonHealthcare & Life Scienceshttps://cadenceneuro.com/

Last Round

Series B

May 17, 2023

Total Funding Raised

$41M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Cadence Neuroscience is a medical technology company that develops implantable neuromodulation therapy devices to treat drug-resistant epilepsy.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Hardware Sales, Hardware + Subscription, Services & Consulting

AI Layer

Non-AI

Keywords

neuromodulation therapyepilepsy treatmentimplantable medical devicefocal drug-resistant epilepsybrain implantneuromod therapyepilepsy deviceneurostimulationcortical stimulationclosed-loop neuromodulationbiomarker-targeted therapyEEG monitoringpediatric epilepsyclinical-stage company

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Cadence Neuroscience Comparables

Compare Cadence Neuroscience with similar companies based on industry and business-model similarity.

Cadence Neuroscience comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Precisis GmbH
82%
Synergia Medical
81%
NeuroPace
79%

Cadence Neuroscience Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 17, 2023
Series ANov 6, 2019

Key People

Founding team and executive leadership

Kent Leyde

CEO

Executive Team

Cadence Neuroscience Investors

Notable investors and investment history

Cadence Neuroscience investors
InvestorRounds
F-Prime CapitalSeries B
JAZZ Venture PartnersSeries B, Series A
Epilepsy FoundationSeries A
Mayo Clinic VenturesSeries A
Angelini VenturesSeries B
F-Prime CapitalSeries B
Lumira VenturesSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 19, 2026

    Monthly visitors increased 33% MoM.

  • Dec 22, 2025

    Daniel (Dan) Moore appointed as Independent Board Director.

Cadence Neuroscience Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Cadence Neuroscience Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Cadence Neuroscience's valuation, stock price, and market status.

Firmographic Details

HeadquartersRedmond, Washington
Employee Range21
Year Founded2017
Last FundingMay 17, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.